Specialty code 174400000X · Miami, FL
NPI
1447295217
Since 2006
Specialty
Specialty code 174400000X
Code 174400000X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
3100 SW 62nd Ave, 1st Floor
Miami, FL, 33155
Phone (305) 663-8595
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$706K
19 prescriptions
Company payments, 2025
$4,819
From 9 companies
Medicare prescription drug claims, 2024
In 2024, the drug Mislen S Bauer prescribed most often to Medicare patients was Vimizim (Elosulfase Alfa), with 11 prescriptions and refills. In total Mislen S Bauer wrote 19 Medicare prescriptions that cost $706K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-08-23.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Vimizim Elosulfase Alfa | 11 | 11 | Under 11 | $705K |
Brand drugs: 13 claims; generic drugs: - claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mislen S Bauer $4,819 ($4,819 in general payments such as food, travel and fees) from 9 companies. The largest payer was BioMarin Pharmaceutical Inc. with $4,426.
| Company | Payments | Amount |
|---|---|---|
| BioMarin Pharmaceutical Inc. BMRN | 5 | $4,426 |
| Alexion Pharmaceuticals, Inc. AZN | 2 | $154 |
| SpringWorks Therapeutics, Inc. | 3 | $75.97 |
| Genzyme Corporation SNY | 1 | $33.87 |
| PTC Therapeutics, Inc. PTCT | 1 | $33.64 |
| Alnylam Pharmaceuticals Inc. ALNY | 1 | $28.22 |
| Mauna Kea Technologies, Inc. ALMKT.PA | 1 | $24.05 |
| Soleno Therapeutics, Inc. SLNO | 1 | $21.59 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 1 | $21.14 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.